Abstract
Objective: Our aim was to determine the performance of abnormal digital rectal examination (DRE) in prostate cancer detection at different PSA levels. Methods: A total of 1612 patients having abnormal DRE and/or elevated PSA whom underwent TRUS guided prostate biopsies were included in the study. Any palpable induration or nodularity was accepted as abnormal DRE findings. Pathologic features of biopsy specimens were compared within groups according to DRE findings and serum PSA level groups of 2.5 - 4, 4 - 10 and >10 ng/ml. Results: Abnormal DRE was detected in 339 patients; of whom 48.7% were determined to have cancer. Cancer detection rates of patients having abnormal DRE were found to be 20%, 31.5% and 68% at PSA ranges 2.5-4, 4-10 and > 10 ng/ml, respectively. Significantly higher grade cancers were detected by abnormal DRE at each PSA group. The positive and negative predictive values of abnormal DRE according to groups of PSA 2.5 - 4, 4 - 10 and > 10 ng/ml were 20% and 84.1%, 31.5% and 80.6%, 68% and 66.6%, respectively. Conclusion: At each PSA group DRE resulted in detecting significantly more cancers with Gleason score > 7. Although predictive value of abnormal DRE diminishes with concomitantly decreasing PSA levels, significance of DRE in the diagnosis of prostate cancer cannot be ignored.
Highlights
Prostate cancer is one of the major causes of cancer-related mortality in the world [1]
The diagnostic investtigation, which primarily aims at identifying the prostate cancer patients in the potentially curable stages is mainly based on two consecutive steps: digital rectal examination (DRE) and serum prostate specific antigen level (PSA) [2,3]
Because these tests are complementary, we evaluated the predictive value and diagnostic performance of DRE in prostate cancer detection at different serum PSA level groups (PSA 2.5 4, 4 - 10 and > 10 ng/ml)
Summary
Prostate cancer is one of the major causes of cancer-related mortality in the world [1]. The optimal usages of these diagnostic tools which bring up the indication of prostate biopsy are subjected to controversies [4]. These controversies are targeted on the predictivity of abnormal DRE findings (induration, asymmetry or irregularity) in the screening of prostate cancer regardless of the serum PSA level and the cut-off levels of serum PSA level for cancer detection regardless of the DRE findings [4]. Because these tests are complementary, we evaluated the predictive value and diagnostic performance of DRE in prostate cancer detection at different serum PSA level groups (PSA 2.5 4, 4 - 10 and > 10 ng/ml)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.